Fluoguide AS (FLUO) - Net Assets
Based on the latest financial reports, Fluoguide AS (FLUO) has net assets worth Skr-2.44 Million SEK (≈ $-263.12K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr29.26 Million ≈ $3.15 Million USD) and total liabilities (Skr31.70 Million ≈ $3.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FLUO goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-2.44 Million |
| % of Total Assets | -8.36% |
| Annual Growth Rate | 285.64% |
| 5-Year Change | 422.94% |
| 10-Year Change | N/A |
| Growth Volatility | 24087.91 |
Fluoguide AS - Net Assets Trend (2018–2024)
This chart illustrates how Fluoguide AS's net assets have evolved over time, based on quarterly financial data. See FLUO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Fluoguide AS (2018–2024)
The table below shows the annual net assets of Fluoguide AS from 2018 to 2024. For live valuation and market cap data, see Fluoguide AS (FLUO) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr23.07 Million ≈ $2.48 Million |
+81.34% |
| 2023-12-31 | Skr12.72 Million ≈ $1.37 Million |
-60.21% |
| 2022-12-31 | Skr31.97 Million ≈ $3.44 Million |
-17.40% |
| 2021-12-31 | Skr38.70 Million ≈ $4.16 Million |
+777.37% |
| 2020-12-31 | Skr4.41 Million ≈ $474.69K |
-2.88% |
| 2019-12-31 | Skr4.54 Million ≈ $488.79K |
+64785.71% |
| 2018-12-31 | Skr7.00K ≈ $753.31 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fluoguide AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2174800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr21.70 Million | 94.10% |
| Common Stock | Skr1.36 Million | 5.90% |
| Total Equity | Skr23.07 Million | 100.00% |
Fluoguide AS Competitors by Market Cap
The table below lists competitors of Fluoguide AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seouleaguer Co. Ltd
KQ:043710
|
$79.01 Million |
|
Heron Therapeuti
NASDAQ:HRTX
|
$79.02 Million |
|
Advero Properties SOCIMI S.A.
MC:YADV
|
$79.03 Million |
|
Thai Wah Public Company Limited
BK:TWPC
|
$79.03 Million |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
$78.98 Million |
|
Daesung Holdin
KO:016710
|
$78.92 Million |
|
Guizhou Zhongyida Co Ltd
SHG:900906
|
$78.92 Million |
|
Nanoform Finland Plc
HE:NANOFH
|
$78.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fluoguide AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,720,000 to 23,067,000, a change of 10,347,000 (81.3%).
- Net loss of 28,959,000 reduced equity.
- New share issuances of 39,301,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-28.96 Million | -125.54% |
| Share Issuances | Skr39.30 Million | +170.38% |
| Other Changes | Skr5.00K | +0.02% |
| Total Change | Skr- | 81.34% |
Book Value vs Market Value Analysis
This analysis compares Fluoguide AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4331.61x to 25.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr0.01 | Skr44.90 | x |
| 2019-12-31 | Skr0.70 | Skr44.90 | x |
| 2020-12-31 | Skr0.45 | Skr44.90 | x |
| 2021-12-31 | Skr3.51 | Skr44.90 | x |
| 2022-12-31 | Skr2.73 | Skr44.90 | x |
| 2023-12-31 | Skr1.07 | Skr44.90 | x |
| 2024-12-31 | Skr1.78 | Skr44.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fluoguide AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -125.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7521.82%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.23x
- Recent ROE (-125.54%) is above the historical average (-286.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -825.97% | 0.00% | 0.00x | 10.71x | Skr-58.52K |
| 2019 | -212.53% | 0.00% | 0.00x | 1.15x | Skr-10.11 Million |
| 2020 | -395.83% | 0.00% | 0.00x | 3.80x | Skr-17.90 Million |
| 2021 | -61.42% | -247.27% | 0.18x | 1.38x | Skr-27.64 Million |
| 2022 | -85.53% | -419.94% | 0.18x | 1.11x | Skr-30.54 Million |
| 2023 | -301.71% | -9072.58% | 0.01x | 2.33x | Skr-39.65 Million |
| 2024 | -125.54% | -7521.82% | 0.01x | 1.23x | Skr-31.27 Million |
Industry Comparison
This section compares Fluoguide AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $159,185,570
- Average return on equity (ROE) among peers: -26.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fluoguide AS (FLUO) | Skr-2.44 Million | -825.97% | N/A | $79.00 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $5.16 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $41.03 Million |
| AcouSort AB (ACOU) | $376.48K | 28.69% | 1.44x | $9.52 Million |
| Active Biotech AB (ACTI) | $46.67 Million | -106.88% | 0.22x | $103.60 Million |
| Alzinova AB (ALZ) | $105.53 Million | -12.38% | 0.06x | $8.00 Million |
| AlzeCure Pharma (ALZCUR) | $233.17 Million | -15.43% | 0.02x | $46.62 Million |
| Annexin Pharmaceuticals AB (ANNX) | $15.57 Million | -63.12% | 0.51x | $9.23 Million |
| Alligator Bioscience AB (ATORX) | $41.44 Million | 0.00% | 0.15x | $11.36 Million |
| BioInvent International AB (BINV) | $49.01 Million | -36.81% | 0.66x | $163.58 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.39 Billion |
About Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more